Erfan Amini1,2, Nariman Ahmadi1, Thomas G Clifford1, Cory M Hugen1, Soroush T Bazargani1, Jie Cai1, Gus Miranda1, Andy E Sherrod3, Siamak Daneshmand1, Hooman Djaladat4,5. 1. Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 2. Department of Urology, Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 4. Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. djaladat@med.usc.edu. 5. Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Suite 7416, Los Angeles, CA, 90089-9178, USA. djaladat@med.usc.edu.
Abstract
PURPOSE: To assess the impact of carcinoma in situ (CIS) on oncologic outcomes in patients who underwent radical cystectomy, with a focus on those who received neoadjuvant chemotherapy (NAC) including patients with down-staging to ≤ pT1cancer after chemotherapy. MATERIALS AND METHODS: All patients who underwent radical cystectomy for urothelial cancer with curative intent from 1985 to 2011 were included. The impact of CIS on recurrence free and overall survival (OS) was assessed in the whole cohort and a subgroup who received NAC as well as those with response to chemotherapy and down-staging to ≤ pT1. RESULTS: A total of 2518 patients with a median follow-up period of 9 years were included. Among all, 1397 (55.5%) had concomitant CIS on final pathology. CIS was associated with high risk pathologic features including high-grade disease, multifocality, and nodal involvement as well as worse recurrence free survival (RFS) with no impact on OS. We did not find a significant association between CIS and oncologic outcomes in a subset of patients who received NAC including those with down-staging to ≤ pT1 disease. In multivariate analysis, CIS had no association with either recurrence free or OS. CONCLUSIONS: Concomitant CIS in radical cystectomy specimens is associated with decreased RFS; however, in multivariate analysis, it was not an independent predicting factor of oncologic outcomes. Moreover, the impact of CIS on oncologic outcomes in a subset of patients who received NAC was insignificant.
PURPOSE: To assess the impact of carcinoma in situ (CIS) on oncologic outcomes in patients who underwent radical cystectomy, with a focus on those who received neoadjuvant chemotherapy (NAC) including patients with down-staging to ≤ pT1cancer after chemotherapy. MATERIALS AND METHODS: All patients who underwent radical cystectomy for urothelial cancer with curative intent from 1985 to 2011 were included. The impact of CIS on recurrence free and overall survival (OS) was assessed in the whole cohort and a subgroup who received NAC as well as those with response to chemotherapy and down-staging to ≤ pT1. RESULTS: A total of 2518 patients with a median follow-up period of 9 years were included. Among all, 1397 (55.5%) had concomitant CIS on final pathology. CIS was associated with high risk pathologic features including high-grade disease, multifocality, and nodal involvement as well as worse recurrence free survival (RFS) with no impact on OS. We did not find a significant association between CIS and oncologic outcomes in a subset of patients who received NAC including those with down-staging to ≤ pT1 disease. In multivariate analysis, CIS had no association with either recurrence free or OS. CONCLUSIONS: Concomitant CIS in radical cystectomy specimens is associated with decreased RFS; however, in multivariate analysis, it was not an independent predicting factor of oncologic outcomes. Moreover, the impact of CIS on oncologic outcomes in a subset of patients who received NAC was insignificant.
Authors: Lars Dyrskjøt; Mogens Kruhøffer; Thomas Thykjaer; Niels Marcussen; Jens L Jensen; Klaus Møller; Torben F Ørntoft Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Shahrokh F Shariat; Ganesh S Palapattu; Pierre I Karakiewicz; Craig G Rogers; Amnon Vazina; Patrick J Bastian; Mark P Schoenberg; Seth P Lerner; Arthur I Sagalowsky; Yair Lotan Journal: Eur Urol Date: 2006-09-11 Impact factor: 20.096
Authors: Philipp Nuhn; Patrick J Bastian; Giacomo Novara; Robert S Svatek; Pierre I Karakiewicz; Eila Skinner; Yves Fradet; Jonathan I Izawa; Wassim Kassouf; Francesco Montorsi; Stefan C Müller; Hans-Martin Fritsche; Guru Sonpavde; Derya Tilki; Hendrik Isbarn; Vincenzo Ficarra; Colin P Dinney; Shahrokh F Shariat Journal: Urol Int Date: 2011-06-09 Impact factor: 2.089
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Shahrokh F Shariat; Pierre I Karakiewicz; Ganesh S Palapattu; Yair Lotan; Craig G Rogers; Gilad E Amiel; Amnon Vazina; Amit Gupta; Patrick J Bastian; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner Journal: J Urol Date: 2006-12 Impact factor: 7.450
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Stephen A Boorjian; Mehrdad Alemozaffar; Badrinath R Konety; Neal D Shore; Leonard G Gomella; Ashish M Kamat; Trinity J Bivalacqua; Jeffrey S Montgomery; Seth P Lerner; Joseph E Busby; Michael Poch; Paul L Crispen; Gary D Steinberg; Anne K Schuckman; Tracy M Downs; Robert S Svatek; Joseph Mashni; Brian R Lane; Thomas J Guzzo; Gennady Bratslavsky; Lawrence I Karsh; Michael E Woods; Gordon Brown; Daniel Canter; Adam Luchey; Yair Lotan; Tracey Krupski; Brant A Inman; Michael B Williams; Michael S Cookson; Kirk A Keegan; Gerald L Andriole; Alexander I Sankin; Alan Boyd; Michael A O'Donnell; David Sawutz; Richard Philipson; Ruth Coll; Vikram M Narayan; F Peter Treasure; Seppo Yla-Herttuala; Nigel R Parker; Colin P N Dinney Journal: Lancet Oncol Date: 2020-11-27 Impact factor: 41.316